ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).-Reference-Cited by-同舟云学术

ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).

Published:2015-05-20 Issue:15_suppl Volume:33 Page:8060-8060
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Felip Enriqueta¹,Orlov Sergey²,Park Keunchil³,Yu Chong-Jen⁴,Tsai Chun-Ming⁵,Nishio Makoto⁶,Cobo Dols Manuel⁷,McKeage Mark James⁸,Su Wu-Chou⁹,Mok Tony¹⁰,Scagliotti Giorgio V.¹¹,Spigel David¹²,Branle Fabrice¹³,Emeremni Chetachi¹⁴,Quadrigli Massimiliano¹³,Shaw Alice Tsang¹⁵

Affiliation:

1. Vall d’Hebron University, Barcelona, Spain

2. Department of Thoracic Oncology, St. Petersburg State Medical University, St. Petersburg, Russia

3. Division of Hematology & Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

4. National Taiwan University, Taipei, Taiwan

5. Taipei Veterans General Hospital, Taipei, Taiwan

6. Japanese Foundation for Cancer Research, Tokyo, Japan

7. Medical Oncology Section, Hospital Regional Universitario Carlos Haya, Málaga, Spain

8. Auckland City Hospital and University of Auckland, Auckland, New Zealand

9. National Cheng Kung University Hospital, Tainan, Taiwan

10. Chinese University of Hong Kong, Shatin, Hong Kong

11. University of Torino, Torino, Italy

12. Medical Oncology, Sarah Cannon Research Institute, Nashville, TN

13. Novartis Pharma AG, Basel, Switzerland

14. Novartis Pharmaceuticals Corporation, East Hanover, NJ

15. Massachusetts General Hospital Cancer Center, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.8060

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23

2. Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis;International Journal of Cancer;2023-06-19

3. Treatment of brain metastases in ALK-positive non-small cell lung cancer;Critical Reviews in Oncology/Hematology;2021-09

4. High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC;Cancers;2021-06-24

5. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma;International Journal of Molecular Sciences;2021-01-08